Lexicon to lay off 50% of field force as it prioritizes heart failure drug, potential US diabetes launch

Despite winning an FDA approval in 2023 and gaining clarity in May on the regulatory path forward for its Type 1 diabetes prospect sotagliflozin, Lexicon Pharmaceuticals hasn’t had an easy go of it in recent years.